134 related articles for article (PubMed ID: 36905817)
1. Comparing the risk of serious infections in patients with and without MS: A German claims data analysis.
Knapp R; Hardtstock F; Wilke T; Maywald U; Chognot C; Craveiro L; Rouzic EM
Mult Scler Relat Disord; 2023 Apr; 72():104583. PubMed ID: 36905817
[TBL] [Abstract][Full Text] [Related]
2. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study.
Knapp R; Hardtstock F; Krieger J; Wilke T; Maywald U; Chognot C; Muros-Le Rouzic E; Craveiro L
Mult Scler Relat Disord; 2022 Dec; 68():104245. PubMed ID: 36306609
[TBL] [Abstract][Full Text] [Related]
3. Electronic health record data for assessing risk of hospitalization for COVID-19: Methodological considerations applied to multiple sclerosis.
Dillon P; Siadimas A; Roumpanis S; Fajardo O; Fitovski K; Jessop N; Whitley L; Muros-Le Rouzic E
Mult Scler Relat Disord; 2023 Mar; 71():104512. PubMed ID: 36716576
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Post-COVID-19-associated morbidity in children, adolescents, and adults: A matched cohort study including more than 157,000 individuals with COVID-19 in Germany.
Roessler M; Tesch F; Batram M; Jacob J; Loser F; Weidinger O; Wende D; Vivirito A; Toepfner N; Ehm F; Seifert M; Nagel O; König C; Jucknewitz R; Armann JP; Berner R; Treskova-Schwarzbach M; Hertle D; Scholz S; Stern S; Ballesteros P; Baßler S; Bertele B; Repschläger U; Richter N; Riederer C; Sobik F; Schramm A; Schulte C; Wieler L; Walker J; Scheidt-Nave C; Schmitt J
PLoS Med; 2022 Nov; 19(11):e1004122. PubMed ID: 36355754
[TBL] [Abstract][Full Text] [Related]
6. Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab.
Nicholas JA; Gudesblatt M; Garabedian M; Belviso N; Shen C; Geremakis C; Shankar SL; Mendoza JP; Lewin JB
Mult Scler Relat Disord; 2022 Jul; 63():103921. PubMed ID: 35700674
[TBL] [Abstract][Full Text] [Related]
7. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data.
Ohlmeier C; Gothe H; Haas J; Osowski U; Weinhold C; Blauwitz S; Schmedt N; Galetzka W; Berkemeier F; Tackenberg B; Stangel M
PLoS One; 2020; 15(5):e0231846. PubMed ID: 32357176
[TBL] [Abstract][Full Text] [Related]
9. Infections in patients diagnosed with multiple sclerosis: A multi-database study.
Persson R; Lee S; Ulcickas Yood M; Wagner Usn Mc CM; Minton N; Niemcryk S; Lindholm A; Evans AM; Jick SS
Mult Scler Relat Disord; 2020 Jun; 41():101982. PubMed ID: 32070858
[TBL] [Abstract][Full Text] [Related]
10. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of pediatric multiple sclerosis in Germany: A nationwide population-based analysis.
Frahm N; Peters M; Bätzing J; Ellenberger D; Akmatov MK; Haas J; Rommer PS; Stahmann A; Zettl UK; Holstiege J
Eur J Neurol; 2021 Sep; 28(9):3173-3176. PubMed ID: 34242461
[TBL] [Abstract][Full Text] [Related]
12. How is and how should healthcare for people with multiple sclerosis in Germany be designed?-The rationale and protocol for the mixed-methods study Multiple Sclerosis-Patient-Oriented Care in Lower Saxony (MS-PoV).
Krüger K; Fricke LM; Dilger EM; Thiele A; Schaubert K; Hoekstra D; Heidenreich F; Brütt AL; Stahmeyer JT; Stahmann A; Röper AL; Kubiak KP; Hemmerling M; Grau A; Eichstädt K; Behrens S; Krauth C
PLoS One; 2021; 16(11):e0259855. PubMed ID: 34762697
[TBL] [Abstract][Full Text] [Related]
13. Infections in patients with multiple sclerosis: A national cohort study in Sweden.
Castelo-Branco A; Chiesa F; Conte S; Bengtsson C; Lee S; Minton N; Niemcryk S; Lindholm A; Rosenlund M; Piehl F; Montgomery S
Mult Scler Relat Disord; 2020 Oct; 45():102420. PubMed ID: 32736217
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Reder AT; Centonze D; Naylor ML; Nagpal A; Rajbhandari R; Altincatal A; Kim M; Berdofe A; Radhakrishnan M; Jung E; Sandrock AW; Smirnakis K; Popescu C; de Moor C
CNS Drugs; 2021 Mar; 35(3):317-330. PubMed ID: 33743151
[TBL] [Abstract][Full Text] [Related]
15. Mapping the risk of infections in patients with multiple sclerosis: A multi-database study in the United Kingdom Clinical Practice Research Datalink GOLD and Aurum.
Leung MW; Bazelier MT; Souverein PC; Uitdehaag BM; Klungel OH; Leufkens HG; Pajouheshnia R
Mult Scler; 2022 Oct; 28(11):1808-1818. PubMed ID: 35575214
[TBL] [Abstract][Full Text] [Related]
16. [Epidemiology of multiple sclerosis in Germany: regional differences and drug prescription in the claims data of the statutory health insurance].
Petersen G; Wittmann R; Arndt V; Göpffarth D
Nervenarzt; 2014 Aug; 85(8):990-8. PubMed ID: 25022894
[TBL] [Abstract][Full Text] [Related]
17. Common comorbidities and survival in MS: Risk for stroke, type 1 diabetes and infections.
Murtonen A; Kurki S; Hänninen K; Soilu-Hänninen M; Sumelahti ML
Mult Scler Relat Disord; 2018 Jan; 19():109-114. PubMed ID: 29190573
[TBL] [Abstract][Full Text] [Related]
18. Use of anti-TNF-α therapy in Crohn's disease is associated with increased incidence of multiple sclerosis.
Avasarala J; Guduru Z; McLouth CJ; Wilburn A; Talbert J; Sutton P; Sokola BS
Mult Scler Relat Disord; 2021 Jun; 51():102942. PubMed ID: 33933908
[TBL] [Abstract][Full Text] [Related]
19. Earnings among people with multiple sclerosis compared to references, in total and by educational level and type of occupation: a population-based cohort study at different points in time.
Wiberg M; Murley C; Tinghög P; Alexanderson K; Palmer E; Hillert J; Stenbeck M; Friberg E
BMJ Open; 2019 Jul; 9(7):e024836. PubMed ID: 31300492
[TBL] [Abstract][Full Text] [Related]
20. Multiple sclerosis by phenotype in Germany.
Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
